Alessandro Crotta

1.7k total citations · 1 hit paper
26 papers, 369 citations indexed

About

Alessandro Crotta is a scholar working on Oncology, Hematology and Immunology. According to data from OpenAlex, Alessandro Crotta has authored 26 papers receiving a total of 369 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Hematology and 9 papers in Immunology. Recurrent topics in Alessandro Crotta's work include CAR-T cell therapy research (14 papers), Hematopoietic Stem Cell Transplantation (7 papers) and Acute Lymphoblastic Leukemia research (5 papers). Alessandro Crotta is often cited by papers focused on CAR-T cell therapy research (14 papers), Hematopoietic Stem Cell Transplantation (7 papers) and Acute Lymphoblastic Leukemia research (5 papers). Alessandro Crotta collaborates with scholars based in United States, Switzerland and France. Alessandro Crotta's co-authors include Manali Kamdar, Jeremy S. Abramson, Jon Arnason, Pim Mutsaers, Sandrine Montheard, Scott R. Solomon, Sami Ibrahimi, Matthew A. Lunning, Alessandro Previtali and Patrick B. Johnston and has published in prestigious journals such as Blood, Molecular Therapy and Haematologica.

In The Last Decade

Alessandro Crotta

22 papers receiving 362 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

2022 186 citations Jeremy S. Abramson, Scott R. Solomon et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alessandro Crotta United States	7	273	121	99	55	50	26	369
Alessandro Previtali United States	7	257 0.9×	111 0.9×	101 1.0×	76 1.4×	43 0.9×	18	374
Sami Ibrahimi United States	9	277 1.0×	158 1.3×	47 0.5×	61 1.1×	66 1.3×	33	387
Houston Holmes United States	12	319 1.2×	146 1.2×	202 2.0×	119 2.2×	79 1.6×	39	540
Paul Maciocia United Kingdom	9	378 1.4×	121 1.0×	85 0.9×	153 2.8×	32 0.6×	23	504
Elizabeth Budde United States	9	161 0.6×	63 0.5×	88 0.9×	48 0.9×	38 0.8×	26	275
LaQuisa Hill United States	11	265 1.0×	66 0.5×	83 0.8×	132 2.4×	31 0.6×	26	368
Matthew L. Ulrickson United States	8	313 1.1×	156 1.3×	28 0.3×	65 1.2×	70 1.4×	35	401
Hien Liu United States	11	449 1.6×	153 1.3×	144 1.5×	67 1.2×	49 1.0×	62	594
Eugenio Galli Italy	9	176 0.6×	43 0.4×	46 0.5×	49 0.9×	29 0.6×	43	280
Pim Mutsaers Netherlands	8	270 1.0×	185 1.5×	28 0.3×	59 1.1×	41 0.8×	30	371

Countries citing papers authored by Alessandro Crotta

Since Specialization

Citations

This map shows the geographic impact of Alessandro Crotta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alessandro Crotta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alessandro Crotta more than expected).

Fields of papers citing papers by Alessandro Crotta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alessandro Crotta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alessandro Crotta. The network helps show where Alessandro Crotta may publish in the future.

Co-authorship network of co-authors of Alessandro Crotta

This figure shows the co-authorship network connecting the top 25 collaborators of Alessandro Crotta. A scholar is included among the top collaborators of Alessandro Crotta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alessandro Crotta. Alessandro Crotta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hunter, Bradley D., Matthew A. Lunning, Sairah Ahmed, et al.. (2025). CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting. Transplantation and Cellular Therapy. 32(2). 171.e1–171.e12. 1 indexed citations

Kamdar, Manali, Sairah Ahmed, Jeremy S. Abramson, et al.. (2025). CT-305: Optimizing Post-Chimeric Antigen Receptor (CAR) T-Cell Monitoring: Evidence Across Lisocabtagene Maraleucel (liso-cel) Pivotal Clinical Trials and Real-World Experience. Clinical Lymphoma Myeloma & Leukemia. 25. S1010–S1011.

Abramson, Jeremy S., Scott R. Solomon, Jon Arnason, et al.. (2024). Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen. Future Oncology. 20(21). 1455–1465. 1 indexed citations

Ghosh, Nilanjan, Alison R. Sehgal, Fei‐Fei Liu, et al.. (2024). Comparative efficacy of lisocabtagene maraleucel in the PILOT study <i>versus</i> second-line chemotherapy regimens in the real world. Haematologica. 110(3). 693–705. 1 indexed citations

Abramson, Jeremy S., Manali Kamdar, Alessandro Crotta, et al.. (2024). Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up. Blood. 144(Supplement 1). 3130–3130.

Morschhauser, Franck, Hervé Ghesquières, Manali Kamdar, et al.. (2023). Comparison of overall survival of lisocabtagene maraleucel (liso‐cel) versus standard of care (SOC) adjusting for crossover in second‐line (2L) R/R large B‐cell lymphoma. Hematological Oncology. 41(S2). 451–452.

Stepan, Lara, Sahar Ansari, Ethan Thompson, et al.. (2023). Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study. Blood. 142(Supplement 1). 225–225. 3 indexed citations

Abramson, Jeremy S., Scott R. Solomon, Jon Arnason, et al.. (2022). Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Compared with Standard of Care (SOC) Using Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study. Transplantation and Cellular Therapy. 28(3). S188–S189.

Abramson, Jeremy S., Patrick B. Johnston, Manali Kamdar, et al.. (2022). Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL. Blood Advances. 6(23). 5969–5979. 17 indexed citations

10.

Abramson, Jeremy S., Manali Kamdar, Fei‐Fei Liu, et al.. (2022). Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL). Blood. 140(Supplement 1). 4655–4656. 1 indexed citations

11.

Abramson, Jeremy S., Scott R. Solomon, Jon Arnason, et al.. (2021). Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study. Blood. 138(Supplement 1). 3845–3845. 6 indexed citations

12.

Crotta, Alessandro, et al.. (2017). Disease Characteristics and Overall Survival in Pediatric Patients with Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia after Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 23(3). S50–S50. 2 indexed citations

13.

Crotta, Alessandro, Jie Zhang, & Christopher Hunt Keir. (2017). Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia. Current Medical Research and Opinion. 34(3). 435–440. 23 indexed citations

14.

Casucci, Monica, Serena Perna, Laura Falcone, et al.. (2013). Graft-versus-leukemia Effect of HLA-haploidentical Central-memory T-cells Expanded With Leukemic APCs and Modified With a Suicide Gene. Molecular Therapy. 21(2). 466–475. 17 indexed citations

15.

Locatelli, Francesco, S. Mandolfo, Giuseppe Villa, et al.. (2013). Efficacy and safety of once-monthly continuous erythropoietin receptor activator in patients with chronic renal anemia. Journal of Nephrology. 26(6). 1114–1121. 10 indexed citations

16.

Mastaglio, Sara, Alessandra Forcina, Isabell Seitz, et al.. (2013). Pharmacokinetics (PK) Study Of Antithymocyte Globulins Fresenius (ATG-F) Prior To Allogeneic Stem Cell Transplantation: Implications For Timing Of Graft and Early Adoptive Immunotherapy Infusions. Blood. 122(21). 4536–4536. 1 indexed citations

17.

Ruggeri, Annalisa, Marie Robin, Alessandro Crotta, et al.. (2012). Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Société Française de Greffe de Moelle-Therapie Cellulaire collaborative study. Bone Marrow Transplantation. 48(2). 253–256. 34 indexed citations

18.

Crotta, Alessandro, Gérard Michel, Guillermo Sanz, et al.. (2010). Incidence and Risk Factors of Chronic Graft-Versus-Host Disease After Unrelated Cord Blood Transplant In Children and Adults. A Retrospective Study on Behalf of EUROCORD and Late-Effect Working Party of EBMT. Blood. 116(21). 219–219. 4 indexed citations

19.

Rocha, Vanderson, Alessandro Crotta, Annalisa Ruggeri, et al.. (2010). Double cord blood transplantation: extending the use of unrelated umbilical cord blood cells for patients with hematological diseases. Best Practice & Research Clinical Haematology. 23(2). 223–229. 43 indexed citations

20.

Vago, Luca, Maria Teresa Lupo Stanghellini, Daniela Clerici, et al.. (2009). Loss of Mismatched HLA as a Mechanism of Leukemia Immune Escape in Family Haploidentical and Unrelated HSCT: Analysis of 103 Transplants From Alternative Donors.. Blood. 114(22). 203–203. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact